Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NAMS Stock Forecast 2026-2027
$30.40
Current Price
$3.55B
Market Cap
Buy 13
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NAMS Price Targets
+94.4%
To High Target of $59.10
+64.6%
To Median Target of $50.04
+22.6%
To Low Target of $37.28
NAMS Price Momentum
-3.6%
1 Week Change
-17.6%
1 Month Change
+50.4%
1 Year Change
-13.3%
Year-to-Date Change
-28.0%
From 52W High of $42.21
+72.4%
From 52W Low of $17.63
📊 TOP ANALYST CALLS
Did NAMS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if NewAmsterdam Pharma is one of their latest high-conviction picks.
Latest NAMS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, NAMS has a bullish consensus with a median price target of $50.04 (ranging from $37.28 to $59.10). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $30.40, the median forecast implies a 64.6% upside. This outlook is supported by 13 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NAMS Analyst Ratings
13
Buy
1
Hold
0
Sell
NAMS Price Target Range
Low
$37.28
Average
$50.04
High
$59.10
Current: $30.40
Latest NAMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NAMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 19, 2026 | Guggenheim | Debjit Chattopadhyay | Buy | Maintains | $45.00 |
| Feb 18, 2026 | Needham | Serge Belanger | Buy | Maintains | $48.00 |
| Jan 21, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Dec 16, 2025 | Stifel | Buy | Maintains | $N/A | |
| Dec 2, 2025 | Goldman Sachs | Neutral | Maintains | $N/A | |
| Nov 6, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Nov 5, 2025 | Needham | Buy | Maintains | $N/A | |
| Oct 20, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Assumes | $52.00 |
| Oct 17, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Aug 25, 2025 | Wells Fargo | Overweight | Initiates | $N/A | |
| Aug 7, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Jul 17, 2025 | Goldman Sachs | Neutral | Initiates | $N/A | |
| Jun 17, 2025 | Citigroup | Buy | Initiates | $N/A | |
| Jun 12, 2025 | Needham | Buy | Reiterates | $N/A | |
| Jun 10, 2025 | Stifel | Buy | Initiates | $N/A | |
| May 8, 2025 | Needham | Buy | Maintains | $N/A | |
| Apr 8, 2025 | Needham | Buy | Reiterates | $N/A | |
| Feb 27, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Feb 27, 2025 | Needham | Buy | Maintains | $N/A | |
| Jan 28, 2025 | RBC Capital | Outperform | Reiterates | $N/A |
NewAmsterdam Pharma Co. N.V. (NAMS) Competitors
The following stocks are similar to NewAmsterdam Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NAMS
NewAmsterdam Pharma
mkt cap
3.55B
NewAmsterdam Pharma Co. N.V. (NAMS) Financial Data
NewAmsterdam Pharma Co. N.V. has a market capitalization of $3.55B with a P/E ratio of -17.0x. The company generates $22.57M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +2.1% quarter-over-quarter, while maintaining an operating margin of -1,921.7% and return on equity of -29.5%.
Valuation Metrics
Market Cap
$3.55B
Enterprise Value
$2.92B
P/E Ratio
-17.0x
PEG Ratio
-1.0x
Price/Sales
157.4x
Growth & Margins
Revenue Growth (YoY)
+2.1%
Gross Margin
N/A
Operating Margin
-1,921.7%
Net Margin
0.0%
EPS Growth
+2.1%
Financial Health
Cash/Price Ratio
+17.9%
Current Ratio
9.8x
Debt/Equity
0.0x
ROE
-29.5%
ROA
-17.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
NewAmsterdam Pharma Co. N.V. (NAMS) Business Model
About NewAmsterdam Pharma Co. N.V.
What They Do
Develops therapies for cardiovascular diseases.
Business Model
NewAmsterdam Pharma operates by researching, developing, and commercializing innovative therapies specifically aimed at addressing cardiovascular diseases. The company generates revenue through the sale of these transformative medications, which are designed to improve patient outcomes and meet the evolving needs of patients worldwide.
Additional Information
As a key player in the pharmaceutical industry, NewAmsterdam Pharma focuses on unmet medical needs within the life sciences sector, aiming for a significant impact on global healthcare. The company emphasizes the necessity of continuous innovation to tackle pressing health challenges, making it a potentially valuable investment opportunity.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
68
CEO
Dr. Michael Harvey Davidson FACC, Facp., M.D.
Country
Netherlands
IPO Year
2022
Website
www.newamsterdampharma.comNewAmsterdam Pharma Co. N.V. (NAMS) Latest News & Analysis
Latest News
Quick Summary
NewAmsterdam Pharma Company N.V. (NAMS) presented at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026.
Why It Matters
NewAmsterdam Pharma's presentation at a major healthcare conference signals potential growth opportunities, product developments, and investor interest, impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma will present data on obicetrapib, an oral therapy for hypercholesterolemia, at the NLA 2026 Scientific Sessions from June 11-14 in Chicago.
Why It Matters
NewAmsterdam's presentation on obicetrapib at a major scientific conference could influence investor sentiment by highlighting potential breakthroughs in treating hypercholesterolemia, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma (Nasdaq: NAMS) will participate in upcoming investor conferences, focusing on its oral, non-statin treatments for cardiovascular disease and elevated LDL-C levels.
Why It Matters
NewAmsterdam's focus on oral, non-statin therapies for cardiovascular disease addresses a significant market need, potentially leading to investment interest and stock volatility surrounding conference updates.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma Company N.V. (NAMS) presented at the Bank of America Global Healthcare Conference 2026, sharing updates relevant to investors.
Why It Matters
NewAmsterdam's presentation at a major healthcare conference signals potential insights into its strategies, pipeline developments, and market positioning, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma Company N.V. (NAMS) has provided an update on the clinical development and interim analysis plans for its PREVAIL trial.
Why It Matters
Updates on clinical trials can impact stock prices. Positive developments may boost confidence in NAMS's future prospects, while setbacks could raise concerns about its valuation and market position.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
NewAmsterdam Pharma (Nasdaq: NAMS) will participate in upcoming investor conferences to discuss its late-stage development of non-statin medicines for cardiovascular disease.
Why It Matters
NewAmsterdam Pharma's participation in investor conferences signals potential growth and opportunity in the biopharmaceutical sector, especially for innovative CVD treatments, influencing stock interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NAMS Stock
What is NewAmsterdam Pharma Co. N.V.'s (NAMS) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, NewAmsterdam Pharma Co. N.V. (NAMS) has a median price target of $50.04. The highest price target is $59.10 and the lowest is $37.28.
Is NAMS stock a good investment in 2026?
According to current analyst ratings, NAMS has 13 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $30.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NAMS stock?
Wall Street analysts predict NAMS stock could reach $50.04 in the next 12 months. This represents a 64.6% increase from the current price of $30.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NewAmsterdam Pharma Co. N.V.'s business model?
NewAmsterdam Pharma operates by researching, developing, and commercializing innovative therapies specifically aimed at addressing cardiovascular diseases. The company generates revenue through the sale of these transformative medications, which are designed to improve patient outcomes and meet the evolving needs of patients worldwide.
What is the highest forecasted price for NAMS NewAmsterdam Pharma Co. N.V.?
The highest price target for NAMS is $59.10 from at , which represents a 94.4% increase from the current price of $30.40.
What is the lowest forecasted price for NAMS NewAmsterdam Pharma Co. N.V.?
The lowest price target for NAMS is $37.28 from at , which represents a 22.6% increase from the current price of $30.40.
What is the overall NAMS consensus from analysts for NewAmsterdam Pharma Co. N.V.?
The overall analyst consensus for NAMS is bullish. Out of 4 Wall Street analysts, 13 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $50.04.
How accurate are NAMS stock price projections?
Stock price projections, including those for NewAmsterdam Pharma Co. N.V., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 9:20 AM UTC